基于肠促胰素的治疗药物在心血管系统中作用的研究进展

【摘要】 心血管疾病(CVD)是糖尿病的大血管并发症之一， 也是致患者死亡的主要原因。 新型药物的心血管安全性是广受关注的问题， 胰高血糖素样肽-1 受体激动剂（GLP-1RA）和二肽基肽酶-4 抑制剂（DPP-4I）是两类通过提高肠促胰素活性治疗 2 型糖尿病（T2DM）的新型药物。 GLP-1RA 和 DPP-4I 对心血管功能异常的动物模型及缺血性心脏病患者的心功能都具有保护作用。 但其对已合并心脏疾病的糖尿病患者心血管系统的作用尚不确定。 本文将近年来关于 GLP-1RA 和 DPP-4I 对心血管系统影响的研究进行综述， 为临床治疗糖尿病及其并发症提供依据。

Advances in Studies on the Effect of Incretin-Based Therapy on Cardiovascular System

Abstract] Cardiovascular disease (CVD) is one of the major complications of type 2 diabetes mellitus (T2DM), which results in a high risk of mortality. Thus, the cardiovascular safety of new anti-diabetic agents has become an important problem with wide concern. There are two classes of incretine-based medications: glucagon-like peptide- 1 receptor agonist (GLP-1RA) and dipeptidyl peptidase-4 (DPP-4) inhibitor (DPP-4I). It has been demonstrated that GLP-1RA and DPP-4I possesse beneficial actions in both animal models of cardiovascular dysfunction and patients with ischemic heart diseases. However, their effects on the cardiovascular system in diabetic patients with heart diseases are still uncertain. Here, we sys-tematically reviewed the effects of GLP-1RA and DPP-4I on cardiovascular system to provide more evidence of incretinbased therapy application for diabetes and complications.